U.S. Cell Therapy Market Share Analysis Report, 2024-2033
The U.S. cell therapy market size was estimated at USD 2.88 billion in 2023 and is projected to hit around USD 19.67 billion by 2033, growing at a CAGR of 21.18% during the forecast period from 2024 to 2033.
Key Takeaways:
U.S. Cell Therapy Market Growth
Major factors contributing to this growth include the growing adoption of regenerative medicine, the rising number of clinical trials on cell therapies due to positive therapeutic outcomes, and the introduction of technological advancements in the market.
The U.S. cell therapy market accounted for a 56% share of the global cell therapy market in 2023. The increasing number of clinical studies on cellular therapies showcases a growing recognition of their potential across various medical conditions. Pharmaceutical companies are increasingly focusing on exploring and utilizing the therapeutic benefits of cells. Over 2,000 clinical trials were ongoing in the cell and gene therapy field as of January 2023, driven by positive outcomes in early-phase trials. These studies target conditions like cancer, autoimmune disorders, and degenerative diseases, aiming to maximize the therapeutic potential of different cell types, including stem cells and immune cells. Moreover, the advancement of genetic editing technologies like CRISPR-Cas9 enables precise modifications to cells' genetic material thereby driving market growth.
In addition, the growing investments and funding for cell therapies are anticipated to enhance competition in the market. Academic and medical institutions are contributing to improving access to cell therapies. For instance, in October 2022, Cedars-Sinai received a 5-year, USD 8 million grant from California's stem cell agency to establish a new clinic aimed at enhancing access to stem cell and gene therapies. This escalating investment and funding for cell therapies is projected to intensify competition within the market.
U.S. Cell Therapy Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 3.49 Billion |
| Market Size by 2033 | USD 19.67 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 21.18% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Therapy type, therapeutic area |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Gilead Sciences, Inc.; Selecta Bioscience; Bristol-Myers Squibb Company; CARGO Therapeutics, Inc.; Johnson & Johnson; Atara Biotherapeutics, Inc; Nkarta, Inc; Cellular Biomedicine Group, Inc; Vertex Pharmaceuticals Incorporated; Aurion Biotech |
Segments Insights:
Therapy Type Insights
Autologous therapies segment dominated the market with a share of 91.9% in 2023. The growth is driven by the personalized nature and potential applications of these therapies in treating a wide range of diseases such as cancer, cardiovascular diseases, neurodegenerative diseases, and orthopedic injuries. Moreover, companies are actively developing cell therapies for cardiovascular diseases. For example, BIOCARDIA, INC. is working on CardiAMP Cell Therapy, an autologous cell therapy designed to treat individuals with ischemic heart failure. This trend of increasing these therapies is expected to drive demand over the forecast period.
Allogenic therapies segment is projected to witness growth at the largest CAGR from 2024 to 2033 owing to widespread use in developing innovative treatment approaches. Allogeneic cell therapies offer advantages over autologous cell therapies, such as immediate availability, scalability, and cost-effectiveness. Moreover, significant companies are expanding the production of allogeneic cell therapies. This trend is poised to drive market growth.
Therapeutic Area Insights
The oncology segment held the market with a share of 92.5% in 2023. The wide applications of cell therapy in the oncology sector are driving the growth. Various cell therapies, including CAR T cell therapies, TCR-based therapies, and allogeneic cord blood-based therapies, are utilized in the treatment of various cancers like blood cancer, melanoma, and multiple myeloma. Additionally, companies increasing their efforts to advance cell therapies for cancer treatment. These features are likely to expand market growth.
The dermatology segment is anticipated to grow at a significant CAGR from 2024 to 2033 owing to advancements in cell therapies for treating skin disorders. Furthermore, the increasing focus of companies on cell therapy for developing dermatological therapeutics is expected to boost the segment growth. For instance, in March 2024, SkinCure Oncology revealed new skin cancer treatment technology at the American Academy of Dermatology Annual Meeting in San Diego. This offers a noninvasive treatment option for non-melanoma skin cancer, providing a targeted and effective approach with high cure rates.
Recent Developments
Some of the prominent players in the U.S. Cell Therapy Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Cell Therapy market.
By Therapy Type
By Therapeutic Area
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product& Service
1.2.2. Application
1.2.3. End-use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Italy
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Cell Therapy Genes Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Cell Therapy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.2. PESTEL Analysis
Chapter 4. U.S. Cell therapy Market Therapy Type Estimates & Trend Analysis
4.1. U.S. Cell Therapy Market Therapy Type Dashboard
4.2. U.S. Cell Therapy Market Therapy Type Movement Analysis
4.3. U.S. Cell Therapy Market Size & Forecasts and Trend Analyses, 2021 - 2033
4.4. Allogeneic Cell Therapy
4.4.1. Allogeneic Cell Therapy Market, 2021 - 2033
4.4.2. Stem Cell Therapies
4.4.2.1. Stem Cell Therapies Market, 2021 - 2033
4.4.2.2. Hematopoeitic Stem Cell Therapies
4.4.2.2.1. Hematopoeitic Stem Cell Therapies, 2021 - 2033
4.4.2.3. Mesenchymal Stem Cell Therapies
4.4.2.3.1. Mesenchymal Stem Cell Therapies, 2021 - 2033
4.4.3. Non-Stem Cell Therapies
4.4.3.1. Non-Stem Cell Therapies, 2021 - 2033
4.4.3.2. Keratinocytes & Fibroblast-Based Therapies
4.4.3.2.1. Keratinocytes & Fibroblast-Based Therapies, 2021 - 2033
4.4.3.3. Other Non-stem Cell Therapies
4.4.3.3.1. Other Non-Stem Cell Therapies, 2021 - 2033
4.5. Autologous Cell Therapy
4.5.1. Autologous Cell Therapy Market, 2021 - 2033
4.5.2. T-Cell Therapies
4.5.2.1. T-Cell Therapies Market, 2021 - 2033
4.5.2.2. CAR-T Cell Therapy
4.5.2.2.1. CAR-T Cell Therapy, 2021 - 2033
4.5.2.3. T-Cell Receptor (TCR)
4.5.2.3.1. T-Cell Receptor (TCR), 2021 - 2033
4.5.3. Others
4.5.3.1. Other Autologous Non-Stem Cell Therapies, 2021 - 2033
Chapter 5. U.S. Cell Therapy Market: Therapeutic Area Estimates & Trend Analysis
5.1. U.S. Cell Therapy Market Therapeutic Area Dashboard
5.2. U.S. Cell Therapy Market Therapeutic Area Movement Analysis
5.3. U.S. Cell Therapy Market Size & Forecasts and Trend Analyses, 2021 - 2033
5.4. Oncology
5.4.1. Oncology Therapies, 2021 - 2033
5.5. Dermatology
5.5.1. Dermatology Therapies, 2021 - 2033
5.6. Others
5.6.1. Other Therapies, 2021 - 2033
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.2.1. Key company market share analysis, 2023
6.3. Vendor Landscape
6.3.1. Gilead Sciences, Inc.
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Product benchmarking
6.3.1.4. Strategic initiatives
6.3.2. Selecta Bioscience
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Product benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Bristol-Myers Squibb Company
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Product benchmarking
6.3.3.4. Strategic initiatives
6.3.4. CARGO Therapeutics, Inc.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Johnson & Johnson
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Atara Biotherapeutics, Inc
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Nkarta, Inc
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Cellular Biomedicine Group, Inc
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. Vertex Pharmaceuticals Incorporated
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Aurion Biotech
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers